Navigation Links
HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research

WILMINGTON, Del., May 18 /PRNewswire/ -- HealthCore, Inc. is developing the Integrated Research Network (IRN(SM)) - a collaborative community of practicing physicians who participate in real-world prospective effectiveness research - in response to increasing need from industry and government to understand more about how drugs and medical devices are performing in patients in real-life settings.

To advance this understanding, HealthCore, the outcomes-based research subsidiary of WellPoint, Inc., is focusing on real-world prospective effectiveness research for healthcare interventions and continued evaluation of marketed drugs and medical devices. These real-world observational studies can be used to generate data about the clinical effectiveness, cost effectiveness and safety of products and devices.

"In the past, decision-makers have been challenged in obtaining applicable outcomes information, because of the artificial nature of findings derived from controlled clinical trials," said Mark Cziraky, HealthCore's vice president of research and development operations.

"HealthCore's research environment allows us to deliver information on how drugs and medical devices are used in the real world to follow patients over extended time periods and to integrate prospective, observational insights with retrospective data," Cziraky said. "The result is realistic, actionable information."

The demand for this kind of research is increasing--post-marketing research is the fastest growing drug development phase, estimated at $12 billion, and growing at 23 percent per year, according to a 2007 report from Research and Markets.

HealthCore will leverage the strengths of the Integrated Research Network--which generates real-world data from practicing physicians--the Healthcare Safety Sentinel System(TM) - a drug safety research system - and WellPoint's database of nearly 35 million members in its affiliated health plans to deliver more accurate and up-to-date information on patient outcomes.

HealthCore's research environment includes one of the largest longitudinal repositories of real-world health plan, practitioner and patient data existing in a single database in the United States.

These research environment assets, combined with HealthCore's experienced clinical and scientific staff, including epidemiologists, physicians, pharmacists, nurses, outcomes researchers, and biostatisticians, allow HealthCore to capture a more complete picture of the actual management of the patient--from the information gathered in the physician's office to their medical and pharmacy claims data--along with their physician's observations.

Among other initiatives, HealthCore is currently working with physicians on a two-year, multi-center prospective, observational study for patents with Type 2 diabetes on a specific therapy. The study is following outcomes and assessing clinical effectiveness in a real-world setting by integrating clinical practice and administrative claims level data.

The IRN(SM) will facilitate and shorten the life-cycle of prospective effectiveness research and comparative effectiveness research initiatives, such as those funded by the $1.1 billion grant program administered by the National Institutes of Health, Agency for Healthcare Research and Quality, and U.S. Department of Health and Human Services.

The IRN(SM) brings together physicians, hospital leaders, clinical researchers and pharmacists to identify clinical issues to study, provide clinical data for ongoing studies, respond to health surveys, and recruit and enroll patients in comparative effectiveness studies.

"Our immediate access to physicians will help facilitate real-world studies that can generate results quickly," said Dr. Louise Short, IRN(SM) medical director for HealthCore. "Our advisory panel of expert physicians, who have experience in community-based practice research and academia, have helped shaped the development of the IRN(SM) to improve the applicability of the data that is generated."

When data collection for a study is complete, this information will be integrated with HealthCore's administrative claims information, including medical and pharmacy utilization, laboratory results and health benefit information on millions of patients, providing additional validity to the economic and clinical outcomes analyses.

About HealthCore

HealthCore, based in Wilmington, Del., is the clinical outcomes research subsidiary of WellPoint. HealthCore has a team of highly experienced researchers including physicians, biostatisticians, pharmacists, epidemiologists, health economists and other scientists who study the "real world" safety and effectiveness of drugs, medical devices and care management interventions. HealthCore offers insight on how to best use this data and communicates these findings to health care decision-makers to support evidence-based medicine, product development decisions, safety monitoring, coverage decisions, process improvement and overall cost-effective health care. For more information, go to

SOURCE HealthCore, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
3. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
4. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
5. CryoLife Responds to Inaccurate Assertions from Plaintiffs Attorney
6. Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
7. Bio-Identical Hormone Menopause Doctor Responds to Recent FDA News About Estriol
8. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
9. MichBio Responds to Governors Plan to Repeal Tort Reform Laws
10. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
11. Neuralstem Responds to New StemCells, Inc. Lawsuit
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... 2015 The Global Genomics ... professional and in-depth study on the current state ... ) , The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
Breaking Biology Technology:
(Date:10/26/2015)... -- Delta ID Inc., a company focused on bringing secure ... announced its ActiveIRIS® technology powers the iris recognition feature ... NTT DOCOMO, INC in Japan . ... include iris recognition technology, after a very successful introduction ... 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , October 23, ... BIOPAC and SensoMotoric Instruments (SMI) announce a mobile plug ... data captured during interactive real-world tasks SensoMotoric ... integration of their established wearable solutions for eye tracking ... gaze behavior captured with SMI Eye Tracking Glasses ...
(Date:10/22/2015)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 30, 2015. --> --> ... percent over the comparable quarter last year to $470.0 million. Net ... or $0.62 per diluted share. --> ... fiscal 2016 grew 39 percent over the prior year period to ...
Breaking Biology News(10 mins):